Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PF-04457845
PF-04457845, FAAH inhibitor · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| PF-04457845 followed by placebo | EXPERIMENTAL | - |
| Placebo followed by PF-04457845 | EXPERIMENTAL | - |
| Naproxen followed by placebo | ACTIVE_COMPARATOR | - |
| Placebo followed by Naproxen | ACTIVE_COMPARATOR | - |
| Cohort 1 (N=10) | EXPERIMENTAL | Placebo-controlled, escalating multiple doses of 0.5mg per day for 14 days. |
| Cohort 2 (N=10) | EXPERIMENTAL | Placebo-controlled, escalating multiple doses of 1mg per day for 14 days. |
| Cohort 3 (N=10) | EXPERIMENTAL | Placebo-controlled, escalating multiple doses of 4mg per day for 14 days. |
| Cohort 4 (N=10) | EXPERIMENTAL | Placebo-controlled, escalating multiple doses of 8mg per day for 14 days. |
| Name | Type | Description |
|---|---|---|
| PF-04457845 | DRUG | PF-04457845 4 mg tablet once daily / matched placebo |
| Naproxen | DRUG | Naproxen 500 mg tablet twice daily / matched placebo |
| PF-04457845, FAAH inhibitor | DRUG | Oral solution of 0.5mg given once daily for 14 days. |
Inclusion Criteria: * Subjects must have a diagnosis of Osteoarthritis (OA) of the knee confirmed by X-ray * Subjects must be willing and able to stop all current pain therapy for the duration of study. (Limited and specific pain therapy will be available throughout the study) * Subjects can be mal...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
PF-04457845 is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE) for the treatment of pain. It has been studied in acute pain and in osteoarthritis of the knee. It is not an approved medicine and remains in clinical development.
PF-04457845 was studied as a treatment for pain in patients with osteoarthritis of the knee. A completed Phase 2 trial, NCT00981357, enrolled 76 patients with knee osteoarthritis across the United States, Canada, and Sweden to investigate whether the drug was effective, safe, and tolerable for treating pain.
PF-04457845 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the clinical trials evaluating the compound in healthy volunteers and in patients with knee osteoarthritis.
PF-04457845 is investigational and has been tested in Phase 1 and Phase 2 clinical trials. It is not FDA approved. A Phase 1 multiple dose trial in healthy volunteers and a Phase 2 trial in knee osteoarthritis have both been completed, and no trials are currently active.
Two completed trials are registered for PF-04457845. NCT00981357 was a Phase 2 study of pain in patients with osteoarthritis of the knee, enrolling 76 participants. NCT00836082 was a Phase 1 multiple dose trial of safety, tolerability, pharmacokinetics, and pharmacodynamics in 41 healthy volunteers in Singapore.